Announcement PDF Doctor Care Anywhere Innovating Healthcare Together: Clinician-Led, Product-Driven FY24 Preliminary Results 27 February 2025 1 Important Notice and Disclaimer This presentation is for information purposes only and it is not financial product or investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Doctor Care Anywhere Group PLC, incorporated in England and Wales with company number 08915336 and registered as a foreign company in Australia ARBN 645 163 873 (the "Company"). In preparing this presentation, the Company did not take into account the investment objectives, financial situation or particular needs of any particular reader. Readers should obtain their own investment, legal and tax advice before taking any action on any information dealt with in the presentation. consequential loss or damage suffered by any person as a result of relying upon any statement in the presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. All amounts are in British pounds (£ or GBP) unless otherwise indicated. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Investors should also be aware that certain financial data included in this presentation including EBITDA and measures described as “pro forma”, are "non-IFRS financial information” under ASIC Regulatory Guide 230 (Disclosing non-IFRS financial information). The non-IFRS financial information financial measures do not have a standardised meaning prescribed by Australian International Financial Reporting Standards (AIFRS) and, therefore, may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other financial measures determined in accordance with AIFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial measures included in this presentation. Neither the Company nor any of its directors, officers, employees, advisors, associated persons or subsidiaries are liable for any direct, indirect or This presentation may contain forward-looking statements regarding the Company’s intent, belief or current expectations with respect to its business and Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. 2 operations, market conditions, results of operations and financial conditions. Words such as ‘will’, ‘may’, ‘expect’, ‘indicative’, ‘plan’, ‘intend’, ‘seek’, ‘would’, ‘should’, ‘risk’, ‘forecast’ and similar expressions indicate forward-looking statements which reflect the Company’s current views with respect to future events and are subject to change and involve risks, uncertainties and assumptions that could cause actual outcomes to differ materially from the outcomes anticipated. Accordingly, readers should not place undue reliance on forward-looking statements. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change. Subject to applicable law, the Company assumes no obligation to update, review or revise any information contained in this presentation, whether as a result of new information, future events or otherwise. Past performance cannot be relied upon as a guide to future performance. References to Doctor Care Anywhere in this presentation are to the Doctor Care Anywhere Group including the Company and all subsidiaries, unless stated otherwise Welcome from CEO Be part of our journey. We have the right people, technology, and clinical experience to seize the UK healthcare market opportunity. Laura O’Riordan CEO, Doctor Care Anywhere 3 Clinician-Led, Product-Driven: Innovating Healthcare Together The NEW leaders that are driving DCA forward Non-Executive Director Chairman John Stier David Ravech Jamie Aspinall Laura O’Riordan Chief Financial Officer Seema Sangar 4 Chief Customer Officer Kristien Bateman Chief Product & Digital Officer Andrew Bellingham Zoe Sullivan Chief Operations Officer Non-Executive Director Dr Sam Shah Matthew Addison Chief of Staff Chief Executive Officer Non-Executive Director Chief Medical Officer Vacancy Who is DCA? We are a business with the winning formula Market Opportunity UK virtual health market value £681.5m (CAGR 17.9% over next 5 years) 7.4m people waiting for NHS treatment and average wait of two weeks to see a GP 5 Scalable Platform Proven Model Right Team 3.1m eligible lives 24/7 service with 100% of patients seen within 24hrs 99.8% platform availability A highly skilled clinical & operational workforce (600+) Trustpilot score 4.1 star Our care model is proven effective, delivering strong outcomes & operational excellence Best Product 711k consultations per year Operational excellence: 96% calls answered in < 60 secs Underlying cash generative in H2 2024 Range of clinician types, primed for future growth Cash reserves to see business through to long term cash generation & profitability Experienced leadership team with backgrounds in digital health Financial Highlights 2024 Continued improvement in all financial metrics £39.3m Revenue (A$77.1m) +9% BAU on FY23 Underlying EBITDA loss reduced to £0.5m (A$1.0m) Down from £5.9m in FY23 6 58% 42% Underlying gross profit margin Underlying contribution margin Up from 46% in FY23 Up from 28% in FY23 Underlying cash generation in H2 2024 £4.4m (A$8.6m) First time in Company’s history metric achieved cash in hand at 31 Dec 2024 Sufficient resources through to profitability Financial Progress 2022-2024 We are pleased to be on a strong path to profitability, driven by strategic growth and efficiency, with momentum building for long-term investor value Revenue (£m) Activated lives by year (‘000) Underlying EBITDA loss (£m) 7 The Market Needs DCA Today In the UK there is an average wait of 2 weeks to see a GP with 7.4 million people currently waiting for treatment Market Product Needs 8 DCA Solutions Highly Accessible Services Rapid Access: 24/7 service, physical & digital, seen in hours not days! Differentiated Value Proposition Personalised Care Pathways: Personalised data drive care outcomes! Cost Management Optimised Cost of Care: Leveraging people and technology Digital-First Care Pathways Digital Integration: Driving self-management care tools Seamless Integration Scalable Solutions: Ability for providers to retain their customer journey Comprehensive Care End to end patient care: Prevention to chronic condition management Sustainable Growth through Strategic Partners The result of investing in our growth is shown through the new partners we have onboarded in 2024 Extending our existing portfolio of current partners… 9 Solutions for End-to-End Care At DCA we are designing and delivering innovative products that seamlessly connect every stage of the healthcare journey High Touch High Complexity Data driven insights & engagement Low cost High volume 10 Example - Our Framework in Musculoskeletal Care In the UK, musculoskeletal conditions accounted for 23.3 million lost workdays in 2022 (est. impact of £2.6b per year), making up around 27% of all work-related absences*. Engagement Navigation & Triage Consultation Enhanced Clinical Support Outcomes Self-help digital tools Request scan or diagnostics Decreased cost of clinical service delivery Decrease lost workdays for partners Patient engages with digital MSK specific content and self-help tools Patient completes digital selfassessment DCA virtual consultation with physiotherapist Face-to-face physiotherapy sessions Digital monitoring tools Virtual physiotherapy sessions Higher engagement of our patients Decreased secondary care costs Meets key market requirements for our partners Provide ongoing support to our patients Differentiate our offering against our competitors Fastrack referral to specialist 11 (*Office for National Statistics) Thank You… We’re in a good place going into 2025 and are poised for a transformative year. Sustainable margin & profit improvements Strong organic growth Innovative 2025 product roadmap New invigorated leadership team 12